News - CRTonline

News

1-20 of 4176 results
1 2 3 4 5 Next »

EARLY TAVR Sub-Analysis Shows Benefits of Early TAVR Regardless of Baseline Biomarker Levels

Mar 31, 2025 by
Bailey G. Salimes, CRTonline.org

Patients with severe, asymptomatic aortic stenosis (AS) benefit from early transcatheter aortic valve replacement (TAVR) regardless of baseline cardiac biomarker levels, but these benefits are more pronounced in patients with lower levels of biomarkers, a sub-analysis of the EARLY TAVR trial shows.

Balloon Angioplasty Guided by IVI Before Stent Implantation Effective for Severely Calcified Lesions: ECLIPSE Trial

Mar 31, 2025 by
Bailey G. Salimes, CRTonline.org

At 1-year, minimal stent area does not increase, and target vessel failure does not decrease, with the use of routine orbital atherectomy pre-drug-eluting stent (DES) implantation compared with using a balloon angioplasty approach in patients with severely calcified lesions, the ECLIPSE trial shows.

Patients With Severe, Asymptomatic AS, AVS and Delayed AVR Show Worse Clinical Outcomes Than Early TAVR Patients: EARLY TAVR Sub-Analysis

Mar 31, 2025 by
Bailey G. Salimes, CRTonline.org

Acute valve syndrome (AVS) plus delayed aortic valve replacement (AVR) is associated with a higher risk of death, stroke or heart failure hospitalization (HFH) in patients with severe aortic stenosis (AS) within 2 years after the procedure, compared with early transcatheter aortic valve replacement (TAVR), a sub-analysis of the EARLY-TAVR trial shows.

EKSTROM Trial Shows Reduction of Plaque Volume Progression in Patients With CAD Taking Colchicine

Mar 31, 2025 by
Bailey G. Salimes, CRTonline.org

Patients with coronary artery disease (CAD) who receive colchicine have lowered total plaque volume 1-year post-coronary computed tomography angiography (CCTA) compared with placebo, and both treatments have similar amounts of low attenuation plaque, a new analysis shows.

Provider Email Notifications Improve Treatment Strategies, Equity Gaps in Patients With Severe AS: DETECT AS Trial

Mar 31, 2025 by
Bailey G. Salimes, CRTonline.org

Electronic provider notifications (EPN) have a significant impact on rates of aortic valve replacement (AVR) in patients with severe, symptomatic aortic stenosis (AS), including improved survival times and narrowing disparity gaps, data from the DETECT AS trial show.

Clopidogrel Tops Aspirin in Monotherapy Post-PCI: SMART-CHOICE 3 Trial Results

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

Patients at high-risk for ischemic events after percutaneous coronary intervention (PCI) who take clopidogrel post-procedure have significantly better outcomes than patients who take aspirin, new data from the SMART-CHOICE 3 trial show.

FAME-3 Trial 5-Year Data Demonstrate Similar Outcomes in PCI vs CABG for 3-Vessel CAD

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

Patients with 3 vessel coronary artery disease (CAD) have similar outcomes in the composite of death, stroke and myocardial infarction (MI) when undergoing fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG), 5-year results from the FAME-3 trial show.

Tricuspid TEER Continues to Improve QoL, Severity of TR, HF Hospitalization Rates: 2-Year TRILUMINATE Study Update

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

At 2-years, tricuspid transcatheter edge-to-edge repair (TEER) is safe and significantly reduces the severity of tricuspid regurgitation (TR) and rates of heart failure hospitalization (HFH) compared to medical therapy alone in patients with severe, symptomatic tricuspid regurgitation.

IVUS, FFR During PCI Have Similar 12-Month Clinical Outcomes: FLAVOUR II Trial

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

Fractional flow reserve (FFR) guidance is noninferior to intravascular ultrasound (IVUS) guidance regarding 12-month clinical outcomes in patients undergoing percutaneous coronary intervention (PCI), data from the FLAVOUR II trial shows.

Evolut Low Risk 5-Year Analysis Shows Similar Outcomes in Patients With AS Undergoing TAVR vs SAVR

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

Patients who are treated with either transcatheter aortic valve replacement (TAVR) with Evolut or surgical AVR (SAVR) for aortic stenosis (AS) have comparable rates of all-cause death or disabling stroke at 5-years, results from the Evolut Low Risk trial show.

JenaValve Trilogy System Exceeds Expectations for 1-Year Safety Endpoint: ALIGN-AR

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

Results from the ALIGN-AR trial, investigating patients with aortic regurgitation (AR) who undergo transcatheter aortic valve replacement (TAVR) with the JenaValve Trilogy system, show that patients have an overall mortality rate of 8.1% at 1-year follow-up, compared with the prespecified goal of 25% to demonstrate noninferiority.

CEP Not Protective Against Stroke in Patients Undergoing TAVI: British Heart Foundation Study

Mar 30, 2025 by
Bailey G. Salimes, CRTonline.org

The incidence of stroke within 3 days is not decreased by routine use of cerebral embolic protection (CEP) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI).

Dapagliflozin Safe in Older Patients With AS, HF Undergoing TAVI

Mar 29, 2025 by
Bailey G. Salimes, CRTonline.org

Dapagliflozin significantly lowers the rate of death from any cause or worsening heart failure (HF) compared with standard care alone in elderly patients with aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI), data from a newly published trial show.

HOST BR Trial Shows 3-Month DAPT Superior to 1-Month in HBR Patients, Noninferior to 12-Months in LBR Patients

Mar 29, 2025 by
Bailey G. Salimes, CRTonline.org

In patients at high bleeding risk (HBR), 3-month dual antiplatelet therapy (DAPT) is superior to 1-month DAPT with similar bleeding risk, and 3-month DAPT is noninferior to 12-month DAPT, and had significantly lower bleeding risk, in patients with low bleeding risk (LBR), a new study shows.

No MACE Differences in Women With INOCA Receiving Intensive Medical Therapy vs Usual Care: WARRIOR Trial

Mar 29, 2025 by
Bailey G. Salimes, CRTonline.org

The first occurrence of all-cause death, myocardial infarction (MI), stroke or hospitalization for worsening angina or heart failure (HF) is not reduced by intensive medical therapy (IMT), compared with usual care (UC) in women with suspected cardiac ischemia without obstructive coronary artery disease (INOCA), data from the WARRIOR trial show.

New Assessment Improves Risk Stratification in Patients Undergoing PCI

Mar 24, 2025 by
Will Chu, CRTonline.org

New research reveals the development of a novel assessment tool that accurately predicts major adverse cardiovascular events (MACE) after a percutaneous coronary intervention (PCI) for true bifurcation lesions.

Novel Balloon-Expandable Valve for Aortic Regurgitation Shows Promising Early Results

Mar 24, 2025 by
Nathan Gray, CRTonline.org

The first transfemoral balloon-expandable transcatheter heart valve for pure native aortic regurgitation (PNAR) shows a low incidence of adverse safety events and good clinical outcomes at 30 days, with notably low rates of paravalvular leak and permanent pacemaker implantation (PPI), early trial data suggests.

DanGer-Shock Analysis Shows Similar Mortality Rates in Non-Arrested Cardiogenic Shock Patients Across Trials

Mar 24, 2025 by
Nathan Gray, CRTonline.org

Patients with infarct-related cardiogenic shock without prior cardiac arrest show similar mortality rates when treated with standard care across multiple mechanical circulatory support (MCS) trials, including the recent DanGer-Shock trial, according to a new post-hoc analysis of randomized trials.

IVL Safe, Effective in Treating Patients With ACS: ACC NCDR Analysis

Mar 21, 2025 by
Bailey G. Salimes, CRTonline.org

A large, real-world study shows that intravascular lithotripsy (IVL) is safe and effective in treating patients with acute coronary syndrome (ACS).

Smokers Are at Greater Risk of Death, MI After PCI With DES: DECADE Analysis

Mar 20, 2025 by
Bailey G. Salimes, CRTonline.org

Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation who are smokers at baseline are at greater risk of death, myocardial infarction (MI) and stent thrombosis (ST) compared with non-smokers, but are at lower risk of repeat revascularization, a long-term pooled analysis shows.

1-20 of 4176 results
1 2 3 4 5 Next »

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details